Melbourne-based mental health technology company Medibio (ASX:MEB) has announced a 'Sponsored Research Agreement' with the Department of Biomedical Sciences of Humanitas University in Milan.
The company said the research agreement will support the continued development of mental health software products and extend its clinical team.
Medibio said it will maintain all intellectual property generated under this agreement.
"Throughout 2019 Medibio will work closely with this highly skilled team of researchers and data scientists who have clinical backgrounds in Psychiatry and Psychology," it said.
"The team’s depth of expertise is impressive, including collectively publishing 177 peer-reviewed articles focusing on subjects like panic attacks, anxiety disorders and general Psychiatry."
“Technology is the future of medicine and this partnership aligns with our focus on continuous innovation, ” said Giorgio Ferrari, the CEO of Humanitas University.
“Transitioning to a modern culture of research, one which expands beyond the university in collaboration with innovative companies like Medibio, is a priority for us. This is an opportunity to improve the precision in diagnostic assessment and therapeutic choices in the field of mental health.”
Dr Giampaolo Perna, Medibio Scientific Advisory Board member, will oversee the collaboration. Dr Perna is currently Chair of the Department of Clinical Neurosciences at San Benedetto Menni Hospital of the Hermanas Hospitalarias (Como Lake) and Academic Coordinator of Mental Health Area and Adjunct Professor at Humanitas University (Milan).
“Medibio has found an effective partner to assist in developing and validating our pipeline of software products,“ said Lindsey Hagan, Medibio Vice President, Strategy and Business Development.
“The ultimate goal of this collaboration is to release clinical products that are meaningful to both physicians and patients while improving outcomes in mental health care delivery.”